Professor
Jiangsu Province Hospital
Nanjing, Jiangsu, China (People's Republic)
Dr. Wang is a pioneer to introduce biotechnology, biopharmaceuticals and interventional cardiology devices into China, funded several drug and device companies in US/China. He guided key animal experiments in US and first-in-human studies in China to prove the concept of Ardian’s renal denervation therapy for hypertension. He has been awarded "CRT 2012 Best Innovation Award" due to his patents of renal sympathetic nerve mapping/ablation devices. He is a co-founder/CMO of SyMap Medical Ltd (its msRDN system obtained approval in China) and was the Vice President, Jiangsu Academy of Clinical and Translational Research/Jiangsu Province Hospital; he is a professor at Jiangsu Province Hospital/Nanjing/China and holds a faculty position at CUMC. He published more than 100 peer-reviewed articles and holds more than 60 patents. He has MD/PhD, completed training at Duke/Harvard.
Disclosure(s): SyMap Medical Ltd, Suzhou, China: Consulting Fees (e.g., advisory boards) (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Salary (Ongoing), Stock-privately held company (Ongoing)
Sunday, March 9, 2025
10:44 AM – 10:52 AM ET
Panel Discussion | Future of Renal Denervation Studies and Clinical Implementation
Sunday, March 9, 2025
11:56 AM – 12:15 PM ET